These multistage pairwise and network meta-analyses presents (1) a summary of the efficacy of statins with or without ezetimibe along the wide spectrum of CKD and (2) the relation of this treatment to reductions in LDLc and CRP with the aim of evaluating the real impact of cholesterol lowering-treatment on CVD in CKD patients. Here, CRP is linked to chronic kidney disease.